European Journal of Radiology
Volume 73, Issue 2 , Pages 255-259 , February 2010

31P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3T

  • Ganesh Nallur Shivu

      Affiliations

    • Department of Cardiovascular Medicine, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
    • Joint First Authors.
    • Corresponding Author InformationCorresponding author. Tel.: +44 1214145916; fax: +44 1214143713.
    • ,
  • Khalid Abozguia

      Affiliations

    • Department of Cardiovascular Medicine, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
    • Joint First Authors.
    • ,
  • Thanh Trung Phan

      Affiliations

    • Department of Cardiovascular Medicine, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
    • Joint First Authors.
    • ,
  • Ibrar Ahmed

      Affiliations

    • Department of Cardiovascular Medicine, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
    • ,
  • Anke Henning

      Affiliations

    • Institute for Biomedical Engineering, University and ETH Zurich, Gloriastrasse 35, CH-8092, Zurich CH ETZ F97, Switzerland
    • ,
  • Michael Frenneaux

      Affiliations

    • Department of Cardiovascular Medicine, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK

Received 11 August 2008 ,Revised 16 October 2008 ,Accepted 21 October 2008.

References 

  1. Bottomley PA. Noninvasive study of high-energy phosphate metabolism in human heart by depth-resolved 31P NMR spectroscopy. Science. 1985;229:769–772
  2. Bittl JA, Ingwall JS. Reaction rates of creatine kinase and ATP synthesis in the isolated rat heart. A 31P NMR magnetization transfer study. J Biol Chem. 1985;260:3512–3517
  3. Weiss RG, Gerstenblith G, Bottomley PA. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci USA. 2005;102:808–813
  4. Nakae I, Mitsunami K, Omura T, et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol. 2003;42:1587–1593
  5. De Sousa E, Veksler V, Minajeva A, et al. Subcellular creatine kinase alterations. Implications in heart failure. Circ Res. 1999;85:68–76
  6. Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med. 2006;3:490–498
  7. Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation. 2006;114:1151–1158
  8. Ye Y, Gong G, Ochiai K, Liu J, Zhang J. High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation. 2001;103:1570–1576
  9. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet. 1991;338:973–976
  10. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190–2196
  11. Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27:942–948
  12. Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med. 1990;323:1593–1600
  13. Maslov MY, Chacko VP, Stuber M, et al. Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice. Am J Physiol Heart Circ Physiol 2007; 292:H387–91.
  14. Neubauer S, Horn M, Pabst T, et al. Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy. J Invest Med. 1997;45:453–462
  15. Conway MA, Bottomley PA, Ouwerkerk R, Radda GK, Rajagopalan B. Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation. 1998;97:1716–1723
  16. Scheuermann-Freestone M, Madsen PL, Manners D, et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107:3040–3046
  17. de Roos A, Doornbos J, Luyten PR, Oosterwaal LJ, van der Wall EE, den Hollander JA. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy. J Magn Reson Imaging. 1992;2:711–719
  18. Sakuma H, Takeda K, Tagami T, et al. 31P MR spectroscopy in hypertrophic cardiomyopathy: comparison with Tl-201 myocardial perfusion imaging. Am Heart J. 1993;125:1323–1328
  19. Jung WI, Sieverding L, Breuer J, et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1998;97:2536–2542
  20. Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776–1782
  21. Lee J, Hu Q, Nakamura Y, et al. Open-chest 31P magnetic resonance spectroscopy of mouse heart at 4.7T. J Magn Reson Imaging. 2006;24:1269–1276
  22. Tyler DJ, Hudsmith LE, Clarke K, Neubauer S, Robson MD. A comparison of cardiac (31)P MRS at 1.5 and 3T. NMR Biomed. 2008;21:793–798
  23. Ordidge RJ, Van de Vyver FL. Re: separate water and fat MR images. Radiology. 1985;157:551–553
  24. Vanhamme L, Sundin T, Hecke PV, Huffel SV. MR spectroscopy quantitation: a review of time-domain methods. NMR Biomed. 2001;14:233–246
  25. Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron-Demilly D. Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed. 2001;14:278–283
  26. Metzler B, Schocke MF, Steinboeck P, et al. Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J Cardiovasc Magn Reson. 2002;4:493–502
  27. Kozerke S, Schar M, Lamb HJ, Boesiger P. Volume tracking cardiac 31P spectroscopy. Magn Reson Med. 2002;48:380–384
  28. Schar M, Kozerke S, Boesiger P. Navigator gating and volume tracking for double-triggered cardiac proton spectroscopy at 3 Tesla. Magn Reson Med. 2004;51:1091–1095
  29. Barker PB, Hearshen DO, Boska MD. Single-voxel proton MRS of the human brain at 1.5 and 3.0 T. Magn Reson Med. 2001;45:765–769
  30. Gruetter R, Weisdorf SA, Rajanayagan V, et al. Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength. J Magn Reson. 1998;135:260–264
  31. Schar M, Kozerke S, Fischer SE, Boesiger P. Cardiac SSFP imaging at 3 Tesla. Magn Reson Med. 2004;51:799–806

PII: S0720-048X(08)00574-3

doi: 10.1016/j.ejrad.2008.10.018

European Journal of Radiology
Volume 73, Issue 2 , Pages 255-259 , February 2010

Article Tools

* Image Usage & Resolution